Comparison of two assays to determine anti-citrullinated peptide antibodies in rheumatoid arthritis in relation to other chronic inflammatory rheumatic diseases: Assaying anti-modified citrullinated vimentin antibodies adds value to second-generation anti-citrullinated cyclic peptides testing

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Díaz Toscano, Miriam Lizette ^a   Olivas Flores, Eva Maria ^b   Zavaleta Muñiz, Soraya Amali ^a   Gamez Nava, Jorge Ivan ^a,c   Cardona Muñoz, Ernesto German ^a   Ponce Guarneros, Manuel ^a   Castro Contreras, Uriel ^d   Nava, Arnulfo ^c,e   Salazar Paramo, Mario ^a,c   Celis, Alfredo ^a   Fajardo Robledo, Nicte Selene ^a   Corona Sanchez, Esther Guadalupe ^a   Gonzalez Lopez, Laura ^a,c,f  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b Hospital General Regional 110   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d SECRETARÍA DE SALUD   (Mexico)

^e UNIVERSIDAD AUTÓNOMA DE GUADALAJARA   (Mexico)

^f Programa de Servicio Social en Investigación Secretaria de Salud ^*  (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; MUTATED CITRULLINATED VIMENTIN ANTIBODY; SECOND GENERATION CYCLIC CITRULLINATED CYCLIC PEPTIDE ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; CITRULLINE; CYCLOPEPTIDE; VIMENTIN;

ADULT; ANTIBODY DETECTION; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOASSAY; INFLAMMATORY DISEASE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ARTHRITIS, RHEUMATOID; BLOOD; DIAGNOSTIC USE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOLOGY; RHEUMATIC FEVER;

ADULT; ANTIBODIES; ARTHRITIS, RHEUMATOID; CITRULLINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RHEUMATIC FEVER; VIMENTIN;

EID: 84904130955     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/198198     Document Type: Article

References (36)

1. Rindfleisch J. A., Muller D., Diagnosis and management of rheumatoid arthritis. The American Family Physician 2005 72 6 1037 1047 2-s2.0-26944465819 (Pubitemid 43093259)
2. Gamez-Nava J. I., Gonzalez-Lopez L., Davis P., Suarez-Almazor M. E., Referral and diagnosis of common rheumatic diseases by primary care physicians. British Journal of Rheumatology 1998 37 11 1215 1219 2-s2.0-0031760657
3. van Boekel M. A. M., Vossenaar E. R., van den Hoogen F. H. J., van Venrooij W. J., Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Research 2002 4 2 87 93 2-s2.0-0036199752 10.1186/ar395 (Pubitemid 34257342)
4. Aletaha D., Neogi T., Silman A. J., 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases 2010 69 1580 1588 2-s2.0-77957262195 10.1136/ard.2010.138461corr1
5. Taylor P., Gartemann J., Hsieh J., Creeden J., A systematic review of serum biomarkers anti-cyclic citrullinated peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Diseases 2011 1 1 2-s2.0-84858757212 10.4061/2011/815038 815038
6. Zintzaras E., Papathanasiou A. A., Ziogas D. C., Voulgarelis M., The reporting quality of studies investigating the diagnostic accuracy of anti-CCP antibody in rheumatoid arthritis and its impact on diagnostic estimates. BMC Musculoskeletal Disorders 2012 13, article 113 2-s2.0-84862624173 10.1186/1471-2474-13-113
7. Poulsom H., Charles P. J., Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis. Clinical Reviews in Allergy and Immunology 2008 34 1 4 10 2-s2.0-49349091092 10.1007/s12016-007-8016-3
8. Wagner E., Skoumal M., Bayer P. M., Klaushofer K., Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatology International 2009 29 11 1315 1321 2-s2.0-69049098891 10.1007/s00296-009-0854-2
9. Dejaco C., Klotz W., Larcher H., Duftner C., Schirmer M., Herold M., Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Research and Therapy 2006 8 4, article R119 2-s2.0-70350615912 10.1186/ar2008
10. Raza K., Mathsson L., Buckley C. D., Filer A., Rönnelid J., Anti-modified citrullinated vimentin (MCV) antibodies in patients with very early synovitis. Annals of the Rheumatic Diseases 2010 69 3 627 628 2-s2.0-77949444541 10.1136/ard.2009.118448
11. Ursum J., Nielen M. M. J., van Schaardenburg D., van der Horst A. R., van de Stadt R. J., Dijkmans B. A. C., Hamann D., Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Research and Therapy 2008 10 1, article R12 2-s2.0-39549108663 10.1186/ar2362 (Pubitemid 351280043)
12. Liu X., Jia R., Zhao J., Li Z., The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis. Journal of Rheumatology 2009 36 6 1136 1142 2-s2.0-67149130596 10.3899/jrheum.080796
13. Bang H., Egerer K., Gauliard A., Lüthke K., Rudolph P. E., Fredenhagen G., Berg W., Feist E., Burmester G.-R., Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis and Rheumatism 2007 56 8 2503 2511 2-s2.0-34547785469 10.1002/art.22817 (Pubitemid 47237269)
14. Besada E., Nikolaisen C., Nossent H., Diagnostic value of antibodies against mutated citrullinated vimentin for rheumatoid arthritis. Clinical and Experimental Rheumatology 2011 29 1 85 88 2-s2.0-79955644931
15. Zhu T., Feng L., Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients. International Journal of Rheumatic Diseases 2013 16 2 157 161 2-s2.0-84879501237 10.1111/1756-185X.12040
16. Bartoloni E., Alunno A., Bistoni O., Bizzaro N., Migliorini P., Morozzi G., Doria A., Mathieu A., Lotzniker M., Allegri F., Riccieri V., Alpini C., Gabrielli A., Tampoia M., Gerli R., Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmunity Reviews 2012 11 11 815 820 2-s2.0-84865402057 10.1016/j.autrev.2012.02.015
17. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S., Medsger T. A. Jr., Mitchell D. M., Neustadt D. H., Pinals R. S., Schaller J. G., Sharp J. T., Wilder R. L., Hunder G. G., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988 31 3 315 324 2-s2.0-0023945481 (Pubitemid 18091653)
18. Doria A., Vesco P., Zulian F., Gambari P. F., The 1982 ARA/ACR criteria for the classification of systemic lupus erythematosus in pediatric and adult patients. Clinical and Experimental Rheumatology 1994 12 6 689 690 2-s2.0-0028544475
19. van der Linden S., Valkenburg H. A., Cats A., Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and Rheumatism 1984 27 4 361 368 2-s2.0-0021272107 (Pubitemid 14134775)
20. Masi A. T., Rodnan G. P., Medsger T. A., Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis and Rheumatism 1980 23 5 581 590 2-s2.0-0018887574
21. Prevoo M. L. L., Van 'T Hof M. A., Kuper H. H., van Leeuwen M. A., van de Putte L. B. A., van Riel P. L. C. M., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism 1995 38 1 44 48 2-s2.0-0028815803 10.1002/art.1780380107
22. Cardiel M. H., Abello-Banfi M., Ruiz-Mercado R., Alarcón-Segovia D., How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). Clinical and Experimental Rheumatology 1993 11 2 117 121 2-s2.0-0027193407 (Pubitemid 23155978)
23. El-Barbary A. M., Kassem E. M., El-Sergany M. A. S., Essa S. A.-M., Eltomey M. A., Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide. Journal of Rheumatology 2011 38 5 828 834 2-s2.0-79955559498 10.3899/jrheum.101143
24. Al-Shukaili A., Al-Ghafri S., Al-Marhoobi S., Alkaabi J., Evaluation of anti-mutated citrullinated vimentin antibodies, anti-cyclic citrullinated peptide antibodies and rheumatoid factor in omani patients with rheumatoid arthritis. International Journal of Rheumatology 2012 2012 5 2-s2.0-84866184276 10.1155/2012/285854 285854
25. Maraina C. H. C., Nurdayana A. K., Rusni D., Azwany Y., Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis. International Journal of Rheumatic Diseases 2010 13 4 335 339 2-s2.0-77958108583 10.1111/j.1756-185X.2010.01552.x
26. Rantapää-Dahlqvist S., De Jong B. A. W., Berglin E., Hallmans G., Wadell G., Stenlund H., Sundin U., van Venrooij W. J., Antibodies against cyclic citrullinated peptide and iga rheumatoid factor predict the development of rheumatoid arthritis. Arthritis and Rheumatism 2003 48 10 2741 2749 2-s2.0-18744430797 10.1002/art.11223 (Pubitemid 37280601)
27. Mathsson L., Mullazehi M., Wick M. C., Sjöberg O., van Vollenhoven R., Klareskog L., Rönnelid J., Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis and Rheumatism 2008 58 1 36 45 2-s2.0-38149026334 10.1002/art.23188
28. Gomez E. L., Gun S. C., Somanath S. D., Chinna K., Radhakrishnan A. K., Ethnic differences in the prognostic utility of rheumatoid factor isotypes and anticyclic citrullinated peptides in rheumatoid arthritis patients: a cross-sectional study. Modern Rheumatology 2013 23 4 716 721 2-s2.0-84880840709 10.1007/s10165-012-0718-6
29. Nicaise-Roland P., Nogueira L., Demattei C., De Chaisemartin L., Rincheval N., Cornillet M., Grootenboer-Mignot S., Dieudé P., Dougados M., Cantagrel A., Meyer O., Serre G., Chollet-Martin S., Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort. Annals of the Rheumatic Diseases 2013 72 3 357 362 2-s2.0-84873702000 10.1136/annrheumdis-2011-201056
30. Vossenaar E. R., Després N., Lapointe E., van der Heijden A., Lora M., Senshu T., van Venrooij W. J., Ménard H. A., Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Research & Therapy 2004 6 2 R142 150 2-s2.0-1842619397
31. Schellekens G. A., de Jong B. A. W., van den Hoogen F. H. J., van de Putte L. B. A., van Venrooij W. J., Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. Journal of Clinical Investigation 1998 101 1 273 281 2-s2.0-0031974911 (Pubitemid 28058927)
32. Verpoort K. N., Cheung K., Ioan-Facsinay A., van der Helm-van Mil A. H. M., De Vries-Bouwstra J. K., Allaart C. F., Drijfhout J. W., De Vries R. R. P., Breedveld F. C., Huizinga T. W. J., Pruijn G. J. M., Toes R. E. M., Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis and Rheumatism 2007 56 12 3949 3952 2-s2.0-37149000281 10.1002/art.23127 (Pubitemid 350262321)
33. Vittecoq O., Inçaurgarat B., Jouen-Beades F., Legoedec J., Letourneur O., Rolland D., Gervasi G., Ménard J. F., Gayet A., Fardellone P., Daragon A., Jolivet M., Loët X. L. E., Tron F., Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clinical and Experimental Immunology 2004 135 1 173 180 2-s2.0-9144244437 10.1111/j.1365-2249.2004.02341.x (Pubitemid 38067943)
34. Saraux A., Berthelot J. M., Devauchelle V., Bendaoud B., Chalés G., Le Henaff C., Thorel J. B., Hoang S., Jousse S., Baron D., Le Goff P., Youinou P., Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. Journal of Rheumatology 2003 30 12 2535 2539 2-s2.0-10744223094 (Pubitemid 37549326)
35. Szekanecz Z., Szabó Z., Zeher M., Soós L., Dankó K., Horváth I., Lakos G., Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population. Immunologic Research 2013 56 2-3 439 443 2-s2.0-84879552101 10.1007/s12026-013-8425-8
36. Shidara K., Inoue E., Tanaka E., Hoshi D., Seto Y., Nakajima A., Momohara S., Taniguchi A., Yamanaka H., Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis. Rheumatology International 2011 31 5 617 622 2-s2.0-79955707162 10.1007/s00296-009-1336-2